BACKGROUND Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with important vascular and hemostatic alterations that should be taken into account during diagnosis and treatment.
A lzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder characterized by amyloid-b (Ab) plaques, tau tangles, neuroinflammation, and brain atrophy (1) . AD is strongly linked with cardiovascular risk factors, and is often accompanied by an important vascular component (2) (3) (4) . The cerebrovascular pathology present in AD includes blood-brain barrier (BBB) disruption, neurovascular unit dysfunction, neurovascular uncoupling, and cerebral blood flow (CBF) alterations (5) (6) (7) . Furthermore, chronic dysregulated hemostasis is present in AD, with increased thrombin generation, presence of activated platelets, and leakage of plasma proteins into the brain parenchyma (8, 9) , favoring the formation and persistence of fibrin clots (10, 11) .
Fibrin(ogen) is up-regulated early in AD (12) , is found intravascularly and extravascularly in areas of synaptic dysfunction and amyloid pathology (10, 11) , and interacts with Ab (13, 14) inducing the formation of resistant clots (10, 15) . Because decreasing systemic fibrin(ogen) levels in AD mice ameliorates disease progression (10, 11, 16) , therapeutics that normalize the prothrombotic environment present in AD might be useful in combination with other strategies (17) . Indeed, traditional anticoagulants have been reported to be beneficial for dementia patients (18, 19) and AD mouse models (20, 21) . However, to overcome their important limitations, such as the necessity for close monitoring and the high risk of bleeding, direct oral anticoagulants (DOACs) have emerged as a useful alternative (22) . Among these, dabigatran is a potent oral direct thrombin inhibitor already approved for several indications, such as the prevention of stroke in patients with nonvalvular atrial fibrillation and the treatment of venous thromboembolism (23) . Dabigatran has minimal drug-drug interactions (22) , a low risk of intracranial bleeding (24, 25) , a potent anti-inflammatory effect (26), and an effective reversal agent available (27) .
Here, we present evidence that long-term anticoagulation with dabigatran ameliorates multiple features of AD pathogenesis. Dabigatran treatment preserved memory and cerebral perfusion in transgenic AD mice, which was accompanied by improved BBB integrity, together with lower levels of fibrin, amyloid deposition, and neuroinflammatory activity in the AD brain.
METHODS

MICE.
TgCRND8 AD mice and nontransgenic littermate controls were provided by The Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Canada (28) . Only female mice were used for this study due to the aggressive behavior of TgCRND8 male littermates, and single housing was not feasible for long-term and behavioral experiments. Seventy female mice were obtained through in vitro fertilization: 37 TgCRND8 and 33 wild-type (WT) mice. Five TgCRND8 mice died before weaning, and 8 died during placebo/dabigatran treatment, which means a 35% loss in TgCRND8 mice, in line with previous studies (28 
RESULTS
TgCRND8 female AD mice and their nontransgenic littermates were fed chow supplemented with dabigatran etexilate or placebo at 8 weeks of age, immediately before amyloid deposition ( Figure 1 ). On the basis of food ingestion per mouse (w5 g), animal
weights throughout the study (26.5 AE 4.0 g), and the 
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TgCRND8 AD mice and WT littermates (n ¼ 13 to 18 female mice/group) started dabigatran/placebo treatment at 8 weeks of age, and were sacrificed after 22 weeks (at 30 weeks of age [30w], n ¼ 8 to 11 mice/group) or 52 weeks of treatment (at 60 weeks of age [60w], n ¼ 5 to 7 mice/group). Histology and WB assays were performed in the 8 experimental groups (WT/30w/placebo, AD/30w/placebo, WT/30w/dabigatran, AD/30w/dabigatran, WT/60w/placebo, AD/60w/placebo, WT/60w/dabigatran, and AD/60w/dabigatran). Blood was extracted before and after treatment to measure dabigatran concentration by diluted thrombin time assays (representative graph is shown). Barnes maze to assess spatial memory performance was performed 17 weeks after the treatment started (at 25 weeks of age, n ¼ 12 to 16 mice/group).
Cerebral perfusion was measured noninvasively by ASL-MRI 32 weeks after treatment started (at 40 weeks of age, n ¼ 5 to 7 mice/group). AD ¼ Alzheimer's disease;
ASL ¼ arterial spin labeling; Dab ¼ dabigatran; MRI ¼ magnetic resonance imaging; WB ¼ Western blot; WT ¼ wild type.
Cortes-Canteli et al. Neuroinflammation in AD is also characterized by infiltration of peripheral T cells into the brain (35) .
We detected an increase in CD3-positive cells Dabigatran Delays Alzheimer's Disease Pathogenesis Double immunofluorescence showed that CD3-positive cells (red) were not inside blood vessels (CD31, green) but rather were extravasated into the brain parenchyma.
(B and F) The cortical area quantified was similar to the one outlined in the low-power images in Figure 5A . Dabigatran Delays Alzheimer's Disease Pathogenesis water channel selectively present in astrocytic perivascular endfeet and essential for Ab clearance and neurovascular coupling (36) . AQP4 was localized around brain blood vessels in 60-week-old WT mice ( Figures 7A and 7B) . However, in age-matched AD mice, astrocyte depolarization was found with AQP4 expression shifting from the astrocytic endfeet surrounding vessels to areas of neuropil near the amyloid plaques ( Figure 7A ). Quantification showed that perivascular AQP4 decreased by 30% in AD mice compared with age-matched WT controls ( Figure 7C ) Because pericytes are also an integral part of the neurovascular unit, we performed immunohistochemical analysis using the pericyte marker plateletderived growth factor receptor-b (PDGFRb). We observed that pericytes in the TgCRND8 AD mice presented abnormal hypertrophic processes surrounding capillaries ( Figure 7D) , similar to what has been described in other transgenic AD mouse lines (37) . Pathological accumulation of cerebral fibrin in the brain parenchyma and inside cerebral blood vessels plays a role on AD pathogenesis (10, 11, 38) . Dabigatran treatment prevented the abnormal deposition of fibrin ( Figure 4) , which may have facilitated the cerebral circulation in the AD mouse brain (Figure 3) . This result is remarkable because CBF alterations precede the onset of dementia (39) . Additionally, long-term anticoagulation decreased amyloid plaques, and, more importantly, halved levels of Ab oligomers (Figure 5) , Immunostaining was performed on brain slices from 60-week-old TgCRND8 AD and WT mice treated with dabigatran/placebo to detect expression and localization of AQP4 and PDGFRb. (A) Double immunofluorescence showed that AQP4 expression (red) was found around blood vessels (CD31 [green]) in the astrocytic endfeet of WT mice. However, AQP4 staining shifted from its perivascular location to neuropil areas surrounding amyloid plaques in AD mice (arrows). (B) Immunohistochemical analysis was performed to segment and quantify the amount of perivascular AQP4 in all experimental groups (C). AD mice treated long term with dabigatran presented significantly more perivascular AQP4 staining than placebo-treated AD mice. Dabigatran Delays Alzheimer's Disease Pathogenesis contributing to decrease primary hemostasis and recruitment of white blood cells into the AD brain.
Furthermore, thrombin, fibrin, and Ab act as proinflammatory mediators in AD (9, 34, 40, 41) . Therefore, the inhibition of thrombin and the resulting decrease Considering that pericyte degeneration in AD contributes to BBB disruption (43) , fibrin extravasation (44) , and depolarization of astrocyte endfeet (45), preservation of pericyte structure and/or function by dabigatran may have contributed to the observed reduction in fibrin content in the AD brain ( Figure 4) and the maintenance of AQP4 at astrocytic endfeet ( Figure 7) . The imbalance between Ab production and clearance through an impaired BBB is considered one of the main pathological processes underlying AD (1).
Our results further support the hypothesis that fibrin and altered hemostasis may be one of the missing links between AD and vascular pathology (8, 17) .
The amelioration of AD-related neuroinflammation, amyloid burden, and BBB dysfunction was observed to be significant only after long-term anticoagulation. Because the procoagulant state in AD is a chronic, sustained process, and fibrin deposition accumulates in the brain as pathology advances with age ( Figure 4 and Cortes-Canteli et al. [11] ), the effect of dabigatran treatment was more robust after longstanding treatment. Indeed, recent epidemiological studies have shown reduced incidence of dementia in atrial fibrillation patients that undergo long-term anticoagulation (46) . Interestingly, we also observed that treatment with dabigatran was accompanied by preservation of cognition (Figure 2) , which is essential for any molecule to be considered a promising therapeutic approach in AD.
Our results indicate that the normalization of the STUDY LIMITATIONS. One of the limitations of anticoagulation in AD is the increased incidence of intracerebral hemorrhage in AD patients due to the presence of cerebral microbleeds (47) and Ab deposition in vessels as cerebral amyloid angiopathy (CAA) (48) . The incidence of both of these vasculopathies is also linked with worse cognitive performance, and the appropriate use of antithrombotic agents in this population is under debate (49) . Dabigatran presents a low risk of intracranial bleeding (24, 25) and does not promote the formation of cerebral microbleeds in AD mice (50) . Furthermore, we observed no hemorrhages or incidents of intracerebral bleeding in any of our animals (data not shown). Nevertheless, use of dabigatran or other antithrombotic agents in AD patients with widespread CAA and cerebral microbleeds will need to be carefully evaluated by a heart-brain team of experts to ensure its use outweighs any bleeding risk (49) . Yet, if dabigatran is used early in the course of the disease, Ab may be cleared more efficiently through the BBB, hence decreasing its deposition in the cortical and leptomeningeal vessels forming CAA. Long-term treatment with dabigatran prevents fibrin deposition in the Alzheimer's disease brain, ameliorating amyloid pathology and neuroinflammation and preserving blood-brain barrier integrity and central blood flow. Ab ¼ amyloid-b; BBB ¼ blood-brain barrier. Twitter: @mcortescanteli.
